Aceragen bags Enzyvant drug and $35M, plots fast path to market
Enzyvant has sold its preclinical Farber disease therapy to Aceragen. NovaQuest Capital Management is funding the newly founded Aceragen, setting the biotech up to enter the clinic and go on to seek approval.